UREA COMPOUND, A METHOD FOR PRODUCTION THEREOF AND MEDICAL USE THEREOF Russian patent published in 2021 - IPC C07D413/12 C07D487/04 C07D401/14 C07D405/14 C07D417/12 C07D473/30 C07D471/04 A61K31/4184 A61K31/422 A61K31/427 A61K31/52 A61P35/02 

FIELD: pharmaceuticals.

SUBSTANCE: invention relates to a compound of general formula (I) or pharmaceutically acceptable salts thereof, where group

is selected from the following structure: , each of R₅¹ and R₅² is independently selected from a group consisting of hydrogen; W and Z are each independently selected from N and C-BR₁; in the absence of R₁, B are identical or different and each is independently selected from a group consisting of hydrogen, halogen, C₁-C₆ alkyl, wherein said C₁-C₆ alkyl optionally further substituted with one or more groups Q; in the presence of R₁, B are identical or different and each is independently selected from a group consisting of -O- and -NR₄-; and R₁ are identical or different and are each independently selected from the group consisting of hydrogen, C₁-C₆ alkyl, heteroaryl, which is a heteroaromatic system containing 1 to 2 heteroatoms, 5 to 6 ring atoms, where the heteroatom is selected from sulfur and nitrogen, -R^uOR^x, -R^uC(O)OR^x, -R^uN(R^y)(R^z), -C(O)N(R^y)(R^z); said alkyl and said heteroaryl is optionally further substituted with one, two or three groups selected from the group consisting of halogen, cyano, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ hydroxyalkoxy, -C(O)NHCH₃, heterocyclyl, which is a saturated monocyclic hydrocarbon group containing from 4 to 6 ring atoms, 1 or 2 of which can be replaced with oxygen and/or nitrogen, halophenyl, C₃-C₆ cycloalkyl-tetrazolyl; R₄ is selected from a group consisting of C₁-C₆ alkyl, or R₄ and R₁ together with the nitrogen atom to which they are attached, form piperazinyl, which is further substituted with one group selected from a group consisting of C₁-C₆ alkyl; R₂ is hydrogen, G is selected from the group:

, which is optionally further substituted with one or two groups selected from a group, consisting of C₁-C₆ alkyl, amino, -C(O)-CH=CH₂, C₃-C₆ cycloalkyl, phenyl and pyridinyl; wherein said C₁-C₆ alkyl or phenyl can be further substituted with one or three groups selected from a group consisting of halogen, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, -C(O)OC₂H₅; R₃ is selected from Q group; R^u is selected from a bond or C₁-C₆ alkylene; R^x is selected from C₁-C₆ alkyl; R^y and R^z are each independently selected from a group consisting of C₁-C₆ alkyl; or R^y and R^z together with the nitrogen atom to which they are attached form a heterocyclyl group containing from 6 to 7 ring atoms, which additionally contains 1 heteroatom selected from nitrogen or oxygen, and heterocyclyl group optionally further substituted with one group, selected from the group consisting of C₁-C₆ alkyl; Q is selected from a group consisting of hydrogen and halogen. Invention also relates to methods of producing said compounds of formula (I).

EFFECT: technical result is obtaining novel compounds which can be used in medicine as a tyrosine protein kinase FLT3 inhibitor for preventing and/or treating a malignant growth.

12 cl, 11 tbl, 134 ex